Beyond the 5‐year milestone: Long‐term survivorship of melanoma patients treated off‐trial with anti‐PD‐1

Little is known about the long‐term outcomes of anti‐PD‐1 treated patients with melanoma beyond 5 years, especially for patients treated off clinical trials. This retrospective cohort study includes patients with unresectable stage III/IV nonuveal melanoma treated with anti‐PD‐1 off‐trial at Memoria...

Full description

Saved in:
Bibliographic Details
Published in:Pigment cell and melanoma research 2023-05, Vol.36 (3-4), p.314-320
Main Authors: Loo, Kimberly, Kalvin, Hannah L., Panageas, Katherine S., Callahan, Margaret K., Chapman, Paul B., Momtaz, Parisa, Shoushtari, Alexander N., Wolchok, Jedd D., Postow, Michael A., Warner, Allison Betof
Format: Article
Language:English
Subjects:
anti‐PD‐1
Clinical trials
Humans
immunotherapy
long‐term survivorship
Medical prognosis
Melanoma
Melanoma - drug therapy
Melanoma, Cutaneous Malignant
off‐trial
Patients
Retrospective Studies
Skin Neoplasms - drug therapy
Survival
Survivorship
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Little is known about the long‐term outcomes of anti‐PD‐1 treated patients with melanoma beyond 5 years, especially for patients treated off clinical trials. This retrospective cohort study includes patients with unresectable stage III/IV nonuveal melanoma treated with anti‐PD‐1 off‐trial at Memorial Sloan Kettering Cancer Center between 2014 and 2017 who survived at least 5 years following their first anti‐PD‐1 dose (N = 139). We characterized overall survival (OS), melanoma‐specific survival (MSS) estimates, treatment‐free survival rates, and subsequent treatment courses. Median follow‐up among 5‐plus year survivors (N = 125) was 78.4 months (range 60.0–96.3). OS at year 7 (2 years post 5‐year landmark) was 90.1% (95% CI: 83.0%–94.3%). Fourteen deaths occurred, seven due to melanoma. MSS at year 7 (2 years post 5‐year landmark) was 95.0% (95% CI: 33.5%–95.2%). In patients who completed anti‐PD‐1 based therapy and did not require subsequent treatment by 5 years (N = 80), the probability of not requiring additional treatment for an additional 2 years was 95.7% (95% CI: 91.0%–100%). Patients treated with anti‐PD‐1 regimens off clinical trials who survive at least 5 years from initial anti‐PD‐1 treatment can be reassured of their excellent long‐term prognosis, particularly if they did not require additional melanoma treatment during the first 5 years.
ISSN:1755-1471
1755-148X
DOI:10.1111/pcmr.13083